{"id":3446,"date":"2026-01-22T15:20:19","date_gmt":"2026-01-22T14:20:19","guid":{"rendered":"https:\/\/www.amsvita.com\/en\/?p=3446"},"modified":"2026-03-28T15:42:35","modified_gmt":"2026-03-28T14:42:35","slug":"biological-aspects-of-autologous-therapy-in-regenerative-medicine","status":"publish","type":"post","link":"https:\/\/www.amsvita.com\/en\/news\/biological-aspects-of-autologous-therapy-in-regenerative-medicine\/","title":{"rendered":"Biological Aspects of Autologous Therapy in Regenerative Medicine"},"content":{"rendered":"\n

Cellular identity and biological compatibility<\/strong><\/h2>\n\n\n\n

Autologous regenerative approaches based on adipose tissue rely on the intrinsic properties of mesenchymal stem\/stromal cells<\/strong> (MSCs) and related stromal elements contained in the stromal vascular fraction (SVF) of fat. Human adipose tissue has been characterized as a source of multipotent mesenchymal stromal\/stem cells, termed adipose-derived stromal cells (ASCs), which share key features with bone marrow\u2013derived MSCs, including plastic adherence, multipotency toward mesodermal lineages, and a characteristic surface marker profile. ASCs are identified within the SVF alongside ASC progenitors, pericytes, and endothelial progenitor cells, forming an interrelated cellular compartment that underpins the biological activity of autologous adipose grafts.<\/p>\n\n\n\n

The cellular identity of ASCs is defined not only by their origin but also by their differentiation and secretory capacities. In vitro, ASCs derived from lipoaspirate samples harvested with different microcannula systems have demonstrated the ability to differentiate toward adipogenic, osteogenic, and chondrogenic<\/strong> lineages, confirming their mesenchymal stemness potential. These cells exhibit classical spindle-shaped mesenchymal morphology and form colony-forming unit fibroblasts (CFU-Fs), further supporting their classification within the MSC family. Such properties are central to the rationale for using autologous adipose tissue as a biologically active graft in regenerative medicine.<\/p>\n\n\n\n

Biological compatibility is inherently favored in autologous therapies because the cellular and matrix components are derived from the same individual. In clinical applications of intra-articular autologous micro-fragmented adipose tissue for osteoarthritis, the injected material has been reported as well tolerated, with postoperative courses characterized only by transient swelling and low-grade pain at the injected joint and minimal discomfort at the donor site. No adverse events such as infection or major complications were observed, and the autologous nature of the graft is explicitly cited as a key factor in its favorable tolerability profile. This underscores the immunologic and biological compatibility of autologous adipose-derived products in joint applications.<\/p>\n\n\n\n

At the tissue level, minimally manipulated micro-fragmented adipose tissue harvested with small-port microcannulas has been shown to contain viable and proliferative cells without the need for enzymatic digestion. Comparative analyses demonstrate that adipose tissue obtained with 0.8 mm and 1 mm side-port cannulas yields a comparable amount of viable cells to tissue processed by standard liposuction followed by collagenase digestion. The preservation of a complex tissue architecture containing adipocytes, stromal cells, and extracellular matrix (ECM) fragments, together with viable SVF cells, provides a biologically compatible autologous product that can be deployed in a single medical procedure without substantial manipulation.<\/p>\n\n\n\n

Role of the stromal niche<\/strong><\/h2>\n\n\n\n

The stromal vascular fraction<\/strong> represents the functional stromal niche within adipose tissue and is central to the biological effects of autologous adipose-based therapies. SVF is composed of ASC progenitors, pericytes, endothelial progenitor cells, and other interrelated cell populations that collectively support tissue repair and regeneration. Adipose-derived stromal cells within this niche are abundant, comprising a notable fraction of the tissue cellularity, and are capable of differentiating into osteoblasts, adipocytes, and chondrocytes, while expressing mesenchymal markers such as CD73, CD90, and CD105 and lacking hematopoietic markers. This cellular composition provides a reservoir of progenitor and supportive cells that can be mobilized through autologous grafting.<\/p>\n\n\n\n

Beyond differentiation, stromal cells and pericytes in adipose tissue secrete a wide variety of bioactive factors with anti-fibrotic, anti-apoptotic, immunomodulatory, and neo-vascularization<\/strong> properties. These paracrine activities are considered critical to the regenerative potential of micro-fragmented adipose grafts, contributing to angiogenesis, modulation of local inflammation, and support of tissue remodeling. In the context of facial aging treatment, adipose tissue harvested with SEFFI and micro-SEFFI systems is specifically designed to deliver viable adipocytes and SVF\/ASCs to restore and regenerate tissues, with stromal cells and pericytes recognized as key mediators of these effects.<\/p>\n\n\n\n

Analytical characterization of micro-SEFFI\u2013derived tissue using non-invasive fractionation technologies has provided further insight into the stromal niche architecture. Fractionation profiles reveal distinct peaks corresponding to large aggregates of adipocytes and ECM, followed by a second peak enriched in cellular elements, including stromal cells. This distribution indicates that the harvested tissue contains both structural matrix components and a concentrated cellular fraction, reflecting an intact stromal microenvironment. Such preservation of the niche may be important for maintaining cell\u2013matrix interactions that influence ASC behavior and survival after transplantation.<\/p>\n\n\n\n

Even when harvested with very small side-port cannulas, micro-SEFFI samples have been shown to yield ASCs that retain robust proliferation and differentiation capacities. Despite lower overall cellularity with decreasing port size, stem cells could be isolated and demonstrated mesenchymal differentiation toward adipogenic, osteogenic, and chondrogenic lineages. These findings support the concept that the adipose stromal niche is resilient to gentle mechanical harvesting and that micro-fragmented adipose tissue, rich in SVF and ASCs, constitutes a biologically active autologous graft suitable for regenerative applications.<\/p>\n\n\n\n

Autologous vs allogeneic approaches<\/strong><\/h2>\n\n\n\n

Autologous regenerative therapy (ART) has been described as an innovative medical discipline that aims to regenerate injured tissues or stimulate their repair using the patient\u2019s own cells in a single medical procedure. In the context of osteoarthritis, ART based on autologous mesenchymal stem cells leverages the capacity of these cells to differentiate in response to environmental signals and growth factors, making them suitable for treating lesions involving cartilage, tendons, and bone. Autologous adipose-derived SVF, obtained through minimally invasive harvesting and intra-articular injection of fat micrografts, has been reported as a safe and feasible approach for managing hip and knee osteoarthritis.<\/p>\n\n\n\n

In clinical series of intra-articular autologous micro-fragmented adipose tissue injections for hip and knee osteoarthritis, the donor site course was uneventful aside from minimal discomfort, edema, and ecchymosis, and no major complications were observed. At the injected joint, only transient swelling and low-grade pain for a few days were reported, without adverse events or infections. The injected material was explicitly noted to be well tolerated because it is autologous. These observations highlight a key advantage of autologous approaches: the reduction of immunologic incompatibility and associated complications, while enabling delivery of viable, patient-derived stromal and progenitor cells.<\/p>\n\n\n\n

From a biological standpoint, autologous adipose tissue provides a microenvironment that is already adapted to the patient\u2019s systemic milieu. The SVF contains ASCs, cytokines, growth factors, pre-adipocytes, and mature adipocytes, all of which contribute to the regenerative effect of fat grafts. ASCs demonstrate the capacity to differentiate into multiple cell types, including adipocytes, chondrocytes, myocytes, hepatocytes, and endothelial cells, and secrete bioactive molecules that stimulate angiogenesis and exert antifibrotic, antiapoptotic, and immunomodulatory effects. When used autologously, these properties can be harnessed without the need for ex vivo expansion or complex cell processing.<\/p>\n\n\n\n

In contrast, culture-expanded stem cell therapies, which may involve allogeneic sources, have been evaluated for intra-articular use in osteoarthritis, with systematic literature reviews focusing on safety. However, the adipose-based clinical experiences described here emphasize autologous SVF and micro-fragmented fat as practical, minimally manipulated options that can be implemented in a single session of approximately 60 to 70 minutes. While broader comparative analyses between autologous and allogeneic strategies are beyond the scope of these data, the available evidence underscores the feasibility, tolerability, and biologically integrated nature of autologous adipose-derived therapies in regenerative medicine.<\/p>\n\n\n\n

Personalized regenerative potential<\/strong><\/h2>\n\n\n\n

Autologous adipose-derived therapies inherently align with the principles of personalized regenerative medicine<\/strong>, as they utilize tissue and cells harvested from the individual patient and reintroduce them into specific anatomical targets. In osteoarthritis management, intra-articular injection of autologous micro-fragmented adipose tissue has been applied to hips and knees after imaging-based evaluation and grading of degenerative changes, allowing treatment to be tailored to the joint involved and the stage of disease. Patients underwent standardized follow-up at one, three, six, and twelve months, enabling longitudinal assessment of pain, range of motion, and functional outcomes.<\/p>\n\n\n\n

Clinical observations suggest that the magnitude and timing of response to autologous adipose-derived SVF may vary according to baseline disease severity and patient characteristics. In the reported cohort, the best clinical results in terms of increased range of motion and reduced stiffness were obtained in younger patients with lower osteoarthritis grades. Improvement in joint mobility appeared around three months, whereas pain reduction, as measured by the Visual Analog Scale, began at three months and reached its peak at six months for the knee and between six and twelve months for the hip. Even in older patients with more severe osteoarthritis, pain reduction was observed, although mobility gains were less pronounced.<\/p>\n\n\n\n

The capacity of ASCs to respond to local environmental cues further supports the personalized nature of autologous therapies. Mesenchymal cells differentiate depending on signals from the surrounding environment and specific growth factors, which positions them as ideal elements to stimulate healing across different tissues. In adipose-derived preparations, this responsiveness is coupled with the presence of cytokines and growth factors within the graft, potentially enabling context-dependent modulation of inflammation, angiogenesis, and matrix remodeling at the target site. Such interactions may contribute to the variable but clinically meaningful improvements reported in diverse patient subgroups.<\/p>\n\n\n\n

In aesthetic and antiaging applications, micro-fragmented adipose tissue rich in SVF and ASCs has been used to improve skin trophism, accelerate closure of complex wounds or ulcers, and enhance skin appearance after radiotherapy damage. The same biological principles\u2014delivery of autologous stromal cells with regenerative and immunomodulatory properties\u2014are applied to different clinical contexts, with treatment plans adapted to the specific tissue defect or degenerative condition. This versatility, grounded in the patient\u2019s own adipose-derived stromal niche, exemplifies how autologous therapies can be integrated into personalized regenerative strategies across musculoskeletal and soft-tissue indications.<\/p>\n\n\n\n

Clinical implications<\/strong><\/h2>\n\n\n\n

Osteoarthritis is characterized by degeneration of articular cartilage, joint pain, dysfunction, and progressive loss of cartilage, particularly in weight-bearing joints such as the knees and hips. Conventional conservative treatments\u2014including physical therapy, weight loss, pharmacologic agents, steroid injections, and intra-articular hyaluronic acid\u2014are largely palliative and do not reverse the degenerative process. In this context, autologous adipose-derived regenerative therapies have emerged as a potential strategy to modify symptoms and functional decline by leveraging the reparative properties of SVF and ASCs.<\/p>\n\n\n\n

In a cohort of 250 patients with initial-stage degenerative hip or knee osteoarthritis treated with intra-articular injection of autologous fat micrograft using a standardized device, clinical follow-up demonstrated increased range of motion, reduced stiffness, and progressive pain reduction over twelve months. On average, range of motion increased by approximately 10 degrees at three months, and the Visual Analog Scale showed a progressive decrease in pain, with the best scores at six months postoperatively. At one year, 85% of patients reported satisfaction with the treatment, citing considerable improvement in pain and quality of life.<\/p>\n\n\n\n

Longer-term follow-up indicated that only a small proportion of patients proceeded to joint replacement surgery within five years, and these were predominantly older individuals with more advanced disease. The satisfactory outcomes of this minimally invasive procedure suggest that intra-articular autologous fat micrograft can replace or considerably delay the need for major joint replacement surgery, with implications for both patient quality of life and healthcare costs. Moreover, treatment with mesenchymal stem cells was considered a good option for improving quality of life in patients with mild or moderate osteoarthritis, and in severe cases for those who refuse surgical treatment, although results remain variable and not yet predictable.<\/p>\n\n\n\n

Safety profiles across these applications have been favorable. Donor site morbidity was limited to minimal discomfort, edema, and ecchymosis, without major complications. Injected joints experienced only transient swelling and low-grade pain, with no reported infections or serious adverse events. Independent studies on adipose tissue harvesting techniques further support the safety and practicality of minimally invasive, small-port microcannula approaches, which yield viable, proliferative cells comparable to those obtained by enzymatic digestion while avoiding regulatory constraints associated with enzymatic processing. Collectively, these findings position autologous adipose-derived therapies as clinically relevant tools within regenerative medicine, particularly for degenerative musculoskeletal and soft-tissue conditions.<\/p>\n\n\n\n

Scientific foundations<\/strong><\/h2>\n\n\n\n

The scientific basis for autologous adipose-derived therapy in regenerative medicine rests on the identification of adipose tissue as a rich and accessible source of multipotent mesenchymal stromal\/stem cells. Foundational work demonstrated that human adipose tissue contains multilineage cells with implications for cell-based therapies and that adipose-derived stem cells are similar to those from bone marrow. Subsequent studies confirmed that adult human adipose tissue harbors several types of multipotent cells and that mesenchymal stem cells may have a perivascular origin in multiple human organs. These insights established adipose tissue as a practical reservoir for autologous MSCs suitable for clinical translation.<\/p>\n\n\n\n

Experimental and translational research has characterized the differentiation potential and immunomodulatory properties of adipose-derived stromal cells. ASCs isolated from nanofat and micro-fragmented lipoaspirates exhibit multilineage potential and immunomodulatory activity in vitro. In the context of facial aging treatment, ASCs derived from SEFFI and micro-SEFFI procedures demonstrated the ability to form CFU-Fs and to differentiate toward adipogenic, osteogenic, and chondrogenic lineages, supporting their stemness and functional relevance. These data provide mechanistic support for the observed clinical effects of autologous adipose grafts in both aesthetic and orthopedic indications.<\/p>\n\n\n\n

Methodological studies have also addressed the impact of harvesting and processing techniques on adipose tissue cell viability. Comparative analyses of adipose tissue harvested with small-port microcannulas versus standard liposuction followed by collagenase digestion showed that minimally manipulated micro-fragmented tissue contains a good amount of viable cells, with similar absorbance-based viability measures at baseline and after 72 hours across techniques. The increase in cell viability over time and the presence of proliferative cells in mechanically harvested tissue support the use of guided microcannula systems as a source of regenerative grafts without the need for enzymatic processing.<\/p>\n\n\n\n

Clinically, the application of autologous adipose-derived SVF in osteoarthritis has been integrated into a broader body of evidence on mesenchymal stem cell therapies for joint disease. Reviews and clinical trials have examined the safety of intra-articular cell therapy with culture-expanded stem cells and the use of adipose-derived stromal vascular fraction cells in osteoarthritis. Within this landscape, the reported experience with intra-articular autologous micro-fragmented adipose tissue confirms that harvesting, SVF isolation, and injection can be performed in a relatively simple, time-efficient session and that the procedure is safe and feasible for hip and knee osteoarthritis. Together, these experimental, methodological, and clinical data form a coherent scientific foundation for the use of autologous adipose-derived therapies in regenerative medicine.<\/p>\n\n\n\n

Sources (Bibliography)<\/strong><\/h2>\n\n\n\n
    \n
  • Trentani P, Meredi E, Zarantonello P, Gennai A. Role of Autologous Micro-Fragmented Adipose Tissue in Osteoarthritis Treatment. Journal of Personalized Medicine, 2024.<\/li>\n\n\n\n
  • Gennai A, Bovani B, Colli M, et al. Comparison of Harvesting and Processing Technique for Adipose Tissue Graft: Evaluation of Cell Viability. International Journal of Regenerative Medicine, 2021.<\/li>\n\n\n\n
  • Rossi M, Alviano F, Ricci F, et al. Characterization of Tissue and Stromal Cells for Facial Aging Treatment Using SEFFI and Micro-SEFFI Systems. Aesthetic Surgery Journal, 2020.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Cellular identity and biological compatibility Autologous regenerative approaches based on adipose tissue rely on the intrinsic properties of mesenchymal stem\/stromal cells (MSCs) and related stromal elements contained in the stromal vascular fraction (SVF) of fat. Human adipose tissue has been characterized as a source of multipotent mesenchymal stromal\/stem cells, termed adipose-derived stromal cells (ASCs), which […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[59,8],"tags":[57,58],"_links":{"self":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts\/3446"}],"collection":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/comments?post=3446"}],"version-history":[{"count":1,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts\/3446\/revisions"}],"predecessor-version":[{"id":3447,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts\/3446\/revisions\/3447"}],"wp:attachment":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/media?parent=3446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/categories?post=3446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/tags?post=3446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}